Loading
Cancer Cells and Metastasis · Journal article
Journal of Translational Medicine · August 13, 2026
Raises a question worth testing. It does not answer one.
This is a critical narrative review of three-dimensional spheroid models for breast cancer research, evaluating their ability to recapitulate tumor complexity, model stem cell-driven resistance, and improve translational predictability. The authors acknowledge substantial utility in modeling microenvironmental features but highlight a persistent translational gap between preclinical findings and patient outcomes, constrained by experimental heterogeneity, incomplete vascular and immune integration, and limited standardization. They propose a tiered, context-driven framework integrating multiple advanced model systems and AI-assisted analytics to advance precision oncology.
Narrative review. Breast cancer research; emphasis on breast cancer stem cell (BCSC) enrichment and therapeutic resistance modeling.
3D spheroid models recapitulate key features of the tumor microenvironment including hypoxia, nutrient gradients, extracellular matrix interactions, and stemness-associated signaling Utility of 3D spheroid models remains constrained by experimental heterogeneity, incomplete vascular and immune integration, and limited cross-platform standardization Conflicting evidence exists regarding predictive drug-response accuracy across 3D spheroid platforms
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review informs researchers and clinicians about the strengths and limitations of 3D spheroid systems for preclinical breast cancer drug development. Clinicians should understand that while 3D models improve upon 2D systems, they do not yet reliably predict patient therapeutic response, and integration with more complex systems (organoids, immune-competent platforms, organ-on-chip) and AI analytics is necessary to bridge the translational gap.
This is a comprehensive narrative review synthesizing existing literature on 3D spheroid models rather than reporting original research data, evidence of efficacy, or definitive clinical outcomes.
As stated by the source record.
This review informs researchers and clinicians about the strengths and limitations of 3D spheroid systems for preclinical breast cancer drug development. Clinicians should understand that while 3D models improve upon 2D systems, they do not yet reliably predict patient therapeutic response, and integration with more complex systems (organoids, immune-competent platforms, organ-on-chip) and AI analytics is necessary to bridge the translational gap.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The limited clinical success of anticancer therapies highlights the need for preclinical models that more accurately recapitulate tumor complexity, therapeutic response, and patient-specific heterogeneity. Conventional two-dimensional (2D) culture systems fail to capture the structural organization, cellular diversity, and dynamic microenvironmental gradients of in vivo tumors, thereby limiting their translational predictive value. Three-dimensional (3D) spheroid models have emerged as widely adopted platforms that better mimic tumor architecture, microenvironmental gradients, and cell–cell interactions. In this review, we provide a comprehensive and critical evaluation of 3D spheroid systems in breast cancer, with particular emphasis on their role in enriching breast cancer stem cells (BCSCs), modeling therapeutic resistance, and improving translational relevance. We comparatively assess scaffold-free and scaffold-based approaches, including hanging drop systems, ultra-low attachment cultures, hydrogels, microfluidics, patient-derived organoids (PDOs), and bioprinting technologies, while clearly distinguishing multicellular tumor spheroids (MCTSs) from organoid-based models according to their structural complexity, self-organization hierarchy, patient-derived fidelity, and translational applicability. While 3D spheroid models recapitulate key features of the tumor microenvironment, including hypoxia, nutrient gradients, extracellular matrix interactions, and stemness-associated signaling, their utility remains constrained by experimental heterogeneity, incomplete vascular and immune integration, and limited cross-platform standardization. We further discuss conflicting evidence regarding predictive drug-response accuracy and examine the persistent translational gap between preclinical findings and patient outcomes. Importantly, we propose a tiered, fit-for-purpose framework for the strategic selection and integration of preclinical cancer models based on the biological question, cancer subtype, and translational objective. Emerging technologies, including patient-derived organoids, vascularized organ-on-chip systems, and AI-assisted analytical platforms, are evaluated as complementary strategies to overcome current biological, technical, and translational limitations. 3D spheroid models represent a critical intermediate platform for physiologically relevant cancer modeling; however, their translational impact depends on integration with more complex, standardized, and clinically validated systems. A multi-model, context-driven approach incorporating advanced bioengineering, immune-competent platforms, AI-assisted analytics, and patient-specific models will be essential for improving translational predictability and advancing precision oncology in breast cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.